| 000 | 01411 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250518072736.0 | ||
| 264 | 0 | _c20210624 | |
| 008 | 202106s 0 0 eng d | ||
| 022 | _a1463-1326 | ||
| 024 | 7 |
_a10.1111/dom.13938 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aInzucchi, Silvio E | |
| 245 | 0 | 0 |
_aAre the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy? _h[electronic resource] |
| 260 |
_bDiabetes, obesity & metabolism _c04 2020 |
||
| 300 |
_a631-639 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aBenzhydryl Compounds _xtherapeutic use |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xepidemiology |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 | _aGlucose |
| 650 | 0 | 4 |
_aGlucosides _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aKidney |
| 700 | 1 | _aFitchett, David | |
| 700 | 1 | _aJurišić-Eržen, Dubravka | |
| 700 | 1 | _aWoo, Vincent | |
| 700 | 1 | _aHantel, Stefan | |
| 700 | 1 | _aJanista, Christina | |
| 700 | 1 | _aKaspers, Stefan | |
| 700 | 1 | _aGeorge, Jyothis T | |
| 700 | 1 | _aZinman, Bernard | |
| 773 | 0 |
_tDiabetes, obesity & metabolism _gvol. 22 _gno. 4 _gp. 631-639 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/dom.13938 _zAvailable from publisher's website |
| 999 |
_c30373958 _d30373958 |
||